India should not be in line for rating downgrade: Kaushik Basu

15 Dec 2012

1

India, which has embarked on a second wave of economic reforms, should not be in the line for downgrade by global rating agencies, World Bank chief economist Kaushik Basu said today.

''India by no means is a prime candidate for downgrading in terms of rating. So especially, with these reforms now in picture India is not in a category to begin worry about downgrading,'' Basu said on the sidelines of Delhi Economic Conclave here.

He said India may see another "harsh" year in terms of economic growth in 2013, hit by the European financial woes "will remain very difficult up to end of 2014", Basu said, adding, "The European situation will remain very difficult up to end of 2014 and may be to the beginning of 2015.''

Basu, who was the chief economic advisor to the finance ministry from December 2009 to July 2012, said there is every chance of the country getting back to the 8-9 per cent growth rate in the next two years.

Credit rating agency Standard & Poor's had, earlier this week, said India faces ''one-in-three'' chance of rating downgrade in the next two years in case the government fails to push reforms ahead of the 2014 general election.

''The negative outlook signals at least a one-in-three likelihood of a downgrade within the next 24 months. A downgrade is likely if India's economic growth prospects dim, its external position deteriorates, its political climate worsens, or fiscal reforms slow,'' S&P said.

Latest articles

South Korean firms unveil $195 billion investment in AI and advanced industries

South Korean firms unveil $195 billion investment in AI and advanced industries

HCLTech wins $1.14 billion AI transformation deal with European client

HCLTech wins $1.14 billion AI transformation deal with European client

Microsoft launches Frontier to help enterprises accelerate AI adoption

Microsoft launches Frontier to help enterprises accelerate AI adoption

AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs

AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs

Trump’s biofuel goals face challenge as US plants lag EPA production targets

Trump’s biofuel goals face challenge as US plants lag EPA production targets

Chris Wood boosts SK Hynix and Samsung bets amid South Korea chip pullback

Chris Wood boosts SK Hynix and Samsung bets amid South Korea chip pullback

Canada backs Greenland molybdenum project with C$7 million grant

Canada backs Greenland molybdenum project with C$7 million grant

India’s $55 billion renewable energy pipeline faces climate risks

India’s $55 billion renewable energy pipeline faces climate risks

Suzlon wins 400 MW Tata Power order, crosses 1 GW partnership milestone

Suzlon wins 400 MW Tata Power order, crosses 1 GW partnership milestone
View details about the software product Informachine File Manager
View details about the software product Informachine News Trackers